Combined anti-leukemic effect of gilteritinib and GSK-J4 in FLT3-ITD+ acute myeloid leukemia
Gilteritinib treats acute myeloid leukemia (AML) with the FMS-like receptor tyrosine kinase-3 (FLT3) internal tandem duplication (ITD) mutation. Dysregulation of histone modification affects the genesis and progression of AML. Strategies targeting key histone regulators have not been applied to the...
Saved in:
Main Authors: | Qi Zhou, Yongyu Guan, Pingping Zhao, Huiyuan Chu, Yaming Xi |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | Translational Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523325000026 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Discovery of novel and highly potent small molecule inhibitors targeting FLT3-ITD for the treatment of acute myeloid leukemia using structure-based virtual screening and biological evaluation
by: Kun Shi, et al.
Published: (2025-02-01) -
Overview of Prognosis of FLT3 Mutations and Interactions with Other Genetic Alterations in Acute Myeloid Leukemia
by: Ayşe Gül Bayrak Tokaç, et al.
Published: (2024-12-01) -
CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells
by: Lucas Touzet, et al.
Published: (2019-03-01) -
Specific emitter identification based on ITD and texture analysis
by: Dong-fang REN, et al.
Published: (2017-12-01) -
Correlation between P-glycoprotein and CD34 Expressions in Leukemic Cells from De novo Acute Myeloid Leukemia
by: Yulia Nadar Indrasari, et al.
Published: (2024-12-01)